{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-003446","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.909871+00:00","generated_at":"2026-05-14T23:57:35.343343+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Valion Bio appoints Melinda Lackey as General Counsel and SVP of Legal Affairs","bullets":["Melinda Lackey, age 49, appointed as GC and SVP of Legal Affairs, effective May 4, 2026.","Prior role: SVP Legal & Administration at Alaunos Therapeutics (TCRT); also served at Kuur Therapeutics and Winston & Strawn.","Employment agreement: base salary $321,000/year, eligible for annual bonus up to 35% of base, and option grant of 45,000 shares.","Lackey will oversee legal functions for Valion's Entolimod ARS program and CDMO subsidiary Velocity Bioworks.","Company (Nasdaq: VBIO) is a clinical-stage immunotherapeutics firm advancing Entolimod via FDA Animal Rule pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-003446","json":"https://secwatch.observer/filing/0001683168-26-003446.json","markdown":"https://secwatch.observer/filing/0001683168-26-003446.md","text":"https://secwatch.observer/filing/0001683168-26-003446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826003446/0001683168-26-003446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826003446/valion_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:57:35.343343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8036818d65","claim":"Melinda Lackey was appointed as General Counsel and Senior Vice President of Legal Affairs at Valion Bio, Inc..","evidence_excerpt":"On May 4, 2026, Melinda Lackey was appointed as General Counsel and Senior Vice President of Legal Affairs of Valion Bio, Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826003446/0001683168-26-003446-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"General Counsel and Senior Vice President of Legal Affairs"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}